当前位置： SCI文献检索 > Targeted Oncology期刊下所有文献 > Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Abstract：

:Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity that may occur in patients receiving anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab and tyrosine kinase inhibitors. Little is known about the characteristics of patients at risk for PRES under anti-VEGF agents. We carried out a comprehensive review of reports documenting the occurrence of PRES in patients receiving anti-VEGF agents. Twenty-six patients are described with a majority of females (73.1%). Almost a third of patients had a past history of hypertension. The most common symptoms included headache, visual disturbance and seizure. A vast majority of patients had hypertension at the diagnosis of PRES, and proteinuria was detectable each time it was investigated. Neurological outcome was favorable in all cases with a symptomatic treatment including blood pressure control. The risk of PRES is increased when blood pressure is poorly controlled and when proteinuria is detectable. The clinical course appears favorable with a symptomatic treatment. PRES is a potentially severe but manageable toxicity of anti-VEGF agents.

journal_name

Target Oncol

journal_title

Targeted oncology

authors

Tlemsani C,Mir O,Boudou-Rouquette P,Huillard O,Maley K,Ropert S,Coriat R,Goldwasser F

doi

10.1007/s11523-011-0201-x

subject

Has Abstract

pub_date

2011-12-01 00:00:00

pages

253-8

issue

4

eissn

1776-2596

issn

1776-260X

journal_volume

6

pub_type

杂志文章,meta分析,评审

相关文献

Targeted Oncology文献大全
  • Sorafenib: A Review in Hepatocellular Carcinoma.

    abstract：:Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall surviva...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-017-0484-7

    authors： Keating GM

    更新日期：2017-04-01 00:00:00

  • Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial.

    abstract：:The First-Line Erbitux in Lung Cancer (FLEX) trial showed that the addition of cetuximab to chemotherapy followed by weekly cetuximab maintenance significantly improved survival in the first-line treatment of advanced non-small cell lung cancer (NSCLC). The phase IIIb NSCLC Erbitux Trial (NEXT) trial (NCT00820755) inv...

    journal_title：Targeted oncology

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s11523-014-0336-7

    authors： Heigener DF,Pereira JR,Felip E,Mazal J,Manzyuk L,Tan EH,Merimsky O,Sarholz B,Esser R,Gatzemeier U

    更新日期：2015-06-01 00:00:00

  • Identification of driver mutations in lung cancer: first step in personalized cancer.

    abstract：:Non-small cell lung cancer (NSCLC) has recently been associated with interesting molecular characteristics that have important implications in carcinogenesis and response to targeted therapies. Targeted therapies, if given to a patient subpopulation enriched by the presence of relevant molecular targets, can often abr...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-013-0263-z

    authors： Planchard D

    更新日期：2013-03-01 00:00:00

  • Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.

    abstract：:Several angiogenesis inhibitors have been approved for commercial use and many additional agents are under development for the treatment of various malignancies. Cardiovascular toxicities have been increasingly recognized as effects of this entire class of new anticancer therapeutics. There is a limited but growing un...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-009-0106-0

    authors： Snider KL,Maitland ML

    更新日期：2009-04-01 00:00:00

  • Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.

    abstract：BACKGROUND:Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL. OBJECTIVE:As the distribution of PTCL subtypes differs between populations and few p...

    journal_title：Targeted oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s11523-019-00630-y

    authors： Hong X,Song Y,Huang H,Bai B,Zhang H,Ke X,Shi Y,Zhu J,Lu G,Liebscher S,Cai C

    更新日期：2019-04-01 00:00:00

  • Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.

    abstract：BACKGROUND:Tyrosine-kinase inhibitors (TKIs) markedly improve progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) mutated for epidermal growth factor receptor (EGFR). Results on overall survival (OS) are less clear-cut. We performed a publication-based meta-analysis to address f...

    journal_title：Targeted oncology

    pub_type： 杂志文章,meta分析

    doi：10.1007/s11523-015-0373-x

    authors： Guetz GD,Landre T,Uzzan B,Chouahnia K,Nicolas P,Morere JF

    更新日期：2016-02-01 00:00:00

  • Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.

    abstract：:Data regarding the expression of epidermal growth factor receptor (EGFR) in melanoma and its role in the tumor biology are conflicting. In BRAF V600-mutant melanomas, the expression of EGFR has been associated with acquired resistance to BRAF inhibitors. In this study, we assessed EGFR expression and downstream signal...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-014-0318-9

    authors： Gross A,Niemetz-Rahn A,Nonnenmacher A,Tucholski J,Keilholz U,Fusi A

    更新日期：2015-03-01 00:00:00

  • Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.

    abstract：:We aimed to assess the prognostic role of pretreatment neutrophilia, lymphocytopenia, and neutrophil to lymphocyte ratio (NLR) in patients treated with vascular endothelial growth factor-tyrosine kinase inhibitors (VEGFR-TKIs) for late relapsing (>5 years) metastatic renal cell carcinoma (mRCC). Data were collected fr...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-014-0356-3

    authors： Santoni M,Buti S,Conti A,Porta C,Procopio G,Sternberg CN,Bracarda S,Basso U,De Giorgi U,Rizzo M,Derosa L,Ortega C,Massari F,Milella M,Bersanelli M,Cerbone L,Muzzonigro G,Burattini L,Montironi R,Santini D,Cascinu S

    更新日期：2015-12-01 00:00:00

  • Renal Toxicities of Targeted Therapies.

    abstract：:With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal tox...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-015-0368-7

    authors： Abbas A,Mirza MM,Ganti AK,Tendulkar K

    更新日期：2015-12-01 00:00:00

  • Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells.

    abstract：BACKGROUND:Hypovitaminosis D is associated with an adverse prognosis in colon cancer patients, possibly due to the effects of the vitamin on the immune system. Antibody-dependent cell-mediated cytotoxicity (ADCC) significantly contributes to the anti-tumor effects of monoclonal antibodies, including cetuximab, an epide...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-018-0586-x

    authors： Mortara L,Gariboldi MB,Bosi A,Bregni M,Pinotti G,Guasti L,Squizzato A,Noonan DM,Monti E,Campiotti L

    更新日期：2018-10-01 00:00:00

  • Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma.

    abstract：:Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotox...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-016-0452-7

    authors： Swamy SG,Kameshwar VH,Shubha PB,Looi CY,Shanmugam MK,Arfuso F,Dharmarajan A,Sethi G,Shivananju NS,Bishayee A

    更新日期：2017-02-01 00:00:00

  • Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.

    abstract：BACKGROUND:Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) cancer are re...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00703-3

    authors： Huang D,Zhang F,Tao H,Zhang S,Ma J,Wang J,Liu Z,Cui P,Chen S,Huang Z,Wu Z,Zhao L,Hu Y

    更新日期：2020-02-01 00:00:00

  • The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.

    abstract：OBJECTIVE:To determine the efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in molecularly selected patients with advanced non-small cell lung cancer (NSCLC), we performed this pooled analysis. METHOD:Randomized trials of EGFR-TKIs as treatment for advanced NSCLC wer...

    journal_title：Targeted oncology

    pub_type： 杂志文章,meta分析,收录出版

    doi：10.1007/s11523-015-0376-7

    authors： Liu J,Sheng Z,Zhang Y,Li G

    更新日期：2016-02-01 00:00:00

  • Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

    abstract：BACKGROUND:The identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions. OBJECTIVE:We assessed changes in programmed cell death-1 (PD1)/PD1 ligand (PDL1) expression in key immunomodulatory cell subsets (myeloid-derived suppressor ...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-018-0595-9

    authors： Tzeng A,Diaz-Montero CM,Rayman PA,Kim JS,Pavicic PG Jr,Finke JH,Barata PC,Lamenza M,Devonshire S,Schach K,Emamekhoo H,Ernstoff MS,Hoimes CJ,Rini BI,Garcia JA,Gilligan TD,Ornstein MC,Grivas P

    更新日期：2018-10-01 00:00:00

  • Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance.

    abstract：:The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the clinical management...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00715-z

    authors： Lorusso D,García-Donas J,Sehouli J,Joly F

    更新日期：2020-06-01 00:00:00

  • Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.

    abstract：BACKGROUND:Serum protein fraction (SPF) is a common parameter reflecting the nutritional and inflammatory status of the human body. However, its role in patients with cancer, particularly those treated with targeted agents, is unknown. OBJECTIVE:We conducted this study to explore the prognostic value of SPF in patient...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-019-00625-9

    authors： Chen X,Yao J,Liu L,Zheng W,Hu X,Zhu Y,Wang H,Guo J

    更新日期：2019-04-01 00:00:00

  • Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.

    abstract：BACKGROUND:Axitinib, an inhibitor of vascular endothelial growth factor (VEGF) receptors, is approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents targeting the VEGF pathway may induce renal toxicities, which may be influenced by pre-existing renal dysfunction. OBJECTIVE:The objective was t...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-015-0389-2

    authors： Chen Y,Rini BI,Motzer RJ,Dutcher JP,Rixe O,Wilding G,Stadler WM,Tarazi J,Garrett M,Pithavala YK

    更新日期：2016-04-01 00:00:00

  • Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.

    abstract：BACKGROUND:The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients. OBJECTIVE:This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity of adavosertib in combination with carboplatin alone or paclitaxel plus carboplatin in Asian patients wi...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00701-5

    authors： Kato H,de Souza P,Kim SW,Lickliter JD,Naito Y,Park K,Kumar S,Mugundu GM,Bang YJ

    更新日期：2020-02-01 00:00:00

  • Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.

    abstract：:Obinutuzumab (Gazyva®, Gazyvaro®) is a recombinant, monoclonal, humanized and glycoengineered, type II, anti-CD20, IgG1 antibody. It has recently been granted an additional indication for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. In the...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-017-0485-6

    authors： Dhillon S

    更新日期：2017-04-01 00:00:00

  • Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment.

    abstract：:Dynamic contrast-enhanced ultrasonography (DCE-US) is a new functional technique enabling a quantitative assessment of solid tumor perfusion using raw linear data. DCE-US allows the calculation of parameters as slope of wash-in or area under the curve (AUC) representing, respectively, blood flow or blood volume. Reduc...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-010-0136-7

    authors： Lassau N,Chebil M,Chami L,Bidault S,Girard E,Roche A

    更新日期：2010-03-01 00:00:00

  • Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study.

    abstract：BACKGROUND:The prognosis of patients with advanced pancreatic cancer is dismal, and there is a need for novel and effective treatments. OBJECTIVES:Tο determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a novel gemcitabine (G) and temsirolimus (T) combination (phase I) and estimate the 6-m...

    journal_title：Targeted oncology

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s11523-018-0605-y

    authors： Karavasilis V,Samantas E,Koliou GA,Kalogera-Fountzila A,Pentheroudakis G,Varthalitis I,Linardou H,Rallis G,Skondra M,Papadopoulos G,Papatsibas G,Sgouros J,Goudopoulou A,Kalogeras KT,Dervenis C,Pectasides D,Fountzilas G

    更新日期：2018-12-01 00:00:00

  • Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).

    abstract：BACKGROUND:The variability in progression-free survival (PFS) and overall survival (OS) among patients with epithelial ovarian cancer (EOC) makes it difficult to reliably predict outcomes. A predictive biomarker of bevacizumab efficacy as first-line therapy in EOC is still lacking. OBJECTIVE:The MITO group conducted a...

    journal_title：Targeted oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s11523-018-0574-1

    authors： Farolfi A,Petrone M,Scarpi E,Gallà V,Greco F,Casanova C,Longo L,Cormio G,Orditura M,Bologna A,Zavallone L,Ventriglia J,Franzese E,Loizzi V,Giardina D,Pigozzi E,Cioffi R,Pignata S,Giorda G,De Giorgi U

    更新日期：2018-08-01 00:00:00

  • Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor.

    abstract：:In subsets of gastrointestinal stromal tumors (GISTs), mutations of the KIT and PDGFRA receptor tyrosine kinases correlate with tumor prognosis and response to tyrosine kinase inhibitors (TKIs). Determining genotypes in TKI-resistant GISTs is challenging due to the potential risks and limitations of repeated biopsies ...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-015-0361-1

    authors： Kang G,Bae BN,Sohn BS,Pyo JS,Kang GH,Kim KM

    更新日期：2015-12-01 00:00:00

  • Vemurafenib-induced progression of breast cancer: a case report and review of the literature.

    abstract：:Vemurafenib, a specific inhibitor of mutated BRAF kinase, may activate wild-type BRAF and therefore induce squamous cell skin carcinomas in patients treated for melanoma. All vemurafenib clinical trials excluded patients with multiple primary malignant tumors; therefore, the action of this drug on concurrent BRAF wild...

    journal_title：Targeted oncology

    pub_type： 杂志文章,评审

    doi：10.1007/s11523-015-0384-7

    authors： Novik AV,Protsenko SA,Baldueva IA,Ivantsov AO,Nekhaeva TL,Akhaeva ZY,Yanus GA,Iyevleva AG,Imyanitov EN

    更新日期：2016-04-01 00:00:00

  • Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.

    abstract：:Among neuroendocrine carcinomas of the gut, well-differentiated tumors are highly vascularized, featuring specific characteristics on contrast-enhanced imaging. Well-differentiated neuroendocrine tumors spontaneously harbor hypervascular enhancement, coexisting with areas of necrosis mainly located at the center of tu...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-012-0216-y

    authors： Faivre S,Ronot M,Dreyer C,Serrate C,Hentic O,Bouattour M,Bruno O,Couvelard A,Vilgrain V,Raymond E

    更新日期：2012-06-01 00:00:00

  • Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.

    abstract：:Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Efficacy of this drug was documented in the BR.21 trial showing that adenocarcinoma, female gender, Asian ethnicity and never-smoker status are predictive of clinical response to erlotinib. Retrospective studies documented the same bene...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-010-0163-4

    authors： Rossi D,Dennetta D,Ugolini M,Catalano V,Alessandroni P,Giordani P,Baldelli AM,Casadei V,Graziano F,Luzi Fedeli S

    更新日期：2010-12-01 00:00:00

  • Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.

    abstract：BACKGROUND:A consistent percentage of patients with metastatic non-small cell lung cancer (NSCLC) derives no or only marginal benefit from immunotherapy (IO). OBJECTIVE:Since serum sodium has been linked to both prognosis in NSCLC and modulation of immune cells activity, we aimed to assess the association between low ...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-018-0599-5

    authors： Fucà G,Galli G,Poggi M,Lo Russo G,Proto C,Imbimbo M,Vitali M,Ganzinelli M,Lanti C,Molino G,Stangoni F,Zilembo N,de Braud F,Garassino MC,Signorelli D

    更新日期：2018-12-01 00:00:00

  • EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.

    abstract：:Basal transcription regulation of the epidermal growth factor receptor is dependent upon a CA simple sequence repeat polymorphism in the intron-1 (CA-SSR-1). Here, we evaluate the role of CA-SSR-1 in complete resected esophageal cancer (EC) patients without neoadjuvant or adjuvant treatment. Genomic DNA was extracted ...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-013-0260-2

    authors： Vashist YK,Trump F,Gebauer F,Kutup A,Güngör C,Kalinin V,Muddasar R,Vettorazzi E,Yekebas EF,Brandt B,Pantel K,Izbicki JR

    更新日期：2014-03-01 00:00:00

  • Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy.

    abstract：BACKGROUND:In 2017, nivolumab monotherapy was shown to be effective as third- or later-line therapy in patients with advanced gastric or gastroesophageal junction cancer. OBJECTIVE:In this study, we investigated the relationship between the neutrophil-to-lymphocyte ratio (NLR) and the outcomes of nivolumab monotherapy...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-020-00716-y

    authors： Yamada T,Hayashi T,Inokuchi Y,Hayashi K,Watanabe H,Komori K,Kano K,Shimoda Y,Fujikawa H,Shiozawa M,Morinaga S,Rino Y,Masuda M,Ogata T,Oshima T

    更新日期：2020-06-01 00:00:00

  • A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.

    abstract：:The discovery of chemoresistant cancer stem cells (CSCs) in carcinomas has created the need for therapies that specifically target these subpopulations of cells. Here, we characterized a bispecific targeted toxin that is composed of two antibody fragments and a catalytic protein toxin allowing it to bind two CSC marke...

    journal_title：Targeted oncology

    pub_type： 杂志文章

    doi：10.1007/s11523-013-0290-9

    authors： Waldron NN,Barsky SH,Dougherty PR,Vallera DA

    更新日期：2014-09-01 00:00:00